Peyrard S - Search Results

1

Effect of contrasted sodium diets on the pharmacokinetics and pharmacodynamic effects of renin-angiotensin system blockers.

Azizi M, Blanchard A, Charbit B, Wuerzner G, Peyrard S, Ezan E, Funck-Brentano C, Ménard J. Azizi M, et al. Among authors: peyrard s. Hypertension. 2013 Jun;61(6):1239-45. doi: 10.1161/HYPERTENSIONAHA.113.01196. Epub 2013 Apr 22. Hypertension. 2013. PMID: 23608658 Clinical Trial.

2

The lactotripeptides isoleucine-proline-proline and valine-proline-proline do not inhibit the N-terminal or C-terminal angiotensin converting enzyme active sites in humans.

Wuerzner G, Peyrard S, Blanchard A, Lalanne F, Azizi M. Wuerzner G, et al. Among authors: peyrard s. J Hypertens. 2009 Jul;27(7):1404-9. doi: 10.1097/HJH.0b013e32832b4759. J Hypertens. 2009. PMID: 19506528

3

Sequential nephron blockade versus sequential renin-angiotensin system blockade in resistant hypertension: a prospective, randomized, open blinded endpoint study.

Bobrie G, Frank M, Azizi M, Peyrard S, Boutouyrie P, Chatellier G, Laurent S, Menard J, Plouin PF. Bobrie G, et al. Among authors: peyrard s. J Hypertens. 2012 Aug;30(8):1656-64. doi: 10.1097/HJH.0b013e3283551e98. J Hypertens. 2012. PMID: 22728905 Clinical Trial.

4

Conformational changes in prorenin during renin inhibition in vitro and in vivo.

Ménard J, Guyene TT, Peyrard S, Azizi M. Ménard J, et al. Among authors: peyrard s. J Hypertens. 2006 Mar;24(3):529-34. doi: 10.1097/01.hjh.0000209989.59230.2e. J Hypertens. 2006. PMID: 16467656 Clinical Trial.

5

Partial human genetic deficiency in tissue kallikrein activity and renal calcium handling.

Blanchard A, Azizi M, Peyrard S, Stern N, Alhenc-Gelas F, Houillier P, Jeunemaitre X. Blanchard A, et al. Among authors: peyrard s. Clin J Am Soc Nephrol. 2007 Mar;2(2):320-5. doi: 10.2215/CJN.02630706. Epub 2007 Jan 3. Clin J Am Soc Nephrol. 2007. PMID: 17699431 Clinical Trial.

6

Genetic and dietary control of plasma tissue kallikrein secretion and urinary kinins exretion in man.

Azizi M, Emanueli C, Peyrard S, Maddedu P, Alhenc-Gelas F, Campbell DJ. Azizi M, et al. Among authors: peyrard s. J Hypertens. 2008 Apr;26(4):714-20. doi: 10.1097/HJH.0b013e3282f4d1fa. J Hypertens. 2008. PMID: 18327081 Clinical Trial.

7

Method of mean value calculation as an additional source of variability in ambulatory blood pressure measurement.

Frank M, Peyrard S, Bobrie G, Azizi M. Frank M, et al. Among authors: peyrard s. Am J Hypertens. 2010 Jul;23(7):725-31. doi: 10.1038/ajh.2010.47. Epub 2010 Mar 25. Am J Hypertens. 2010. PMID: 20339354

8

Aldosterone synthase inhibition with LCI699: a proof-of-concept study in patients with primary aldosteronism.

Amar L, Azizi M, Menard J, Peyrard S, Watson C, Plouin PF. Amar L, et al. Among authors: peyrard s. Hypertension. 2010 Nov;56(5):831-8. doi: 10.1161/HYPERTENSIONAHA.110.157271. Epub 2010 Sep 13. Hypertension. 2010. PMID: 20837883 Clinical Trial.

9

Antinatriuretic effect of vasopressin in humans is amiloride sensitive, thus ENaC dependent.

Blanchard A, Frank M, Wuerzner G, Peyrard S, Bankir L, Jeunemaitre X, Azizi M. Blanchard A, et al. Among authors: peyrard s. Clin J Am Soc Nephrol. 2011 Apr;6(4):753-9. doi: 10.2215/CJN.06540810. Epub 2011 Jan 13. Clin J Am Soc Nephrol. 2011. PMID: 21233458 Free PMC article.

10

Sequential comparison of aldosterone synthase inhibition and mineralocorticoid blockade in patients with primary aldosteronism.

Amar L, Azizi M, Menard J, Peyrard S, Plouin PF. Amar L, et al. Among authors: peyrard s. J Hypertens. 2013 Mar;31(3):624-9; discussion 629. doi: 10.1097/HJH.0b013e32835d6d49. J Hypertens. 2013. PMID: 23314743

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

63 results

Search Page

Filters